PC1-CTT Polypeptide Gene Therapy for ADPKD mTOR Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Autosomal Dominant Polycystic Kidney Disease (ADPKD) are limited in effectiveness and safety, with no known treatments that can reverse the disease, and existing therapies only slow progression or have adverse effects, leading to significant morbidity and mortality for patients.
Innovation Solution
The use of transgenic expression of a 200 amino acid fragment of the Polycystin-1 protein, specifically a C-terminal fragment (PC1-CTT), to suppress disease development by interacting with nicotinamide nucleotide transhydrogenase (NNT), potentially through gene therapy compositions that include therapeutic polypeptides and nucleic acids, which can be administered to reduce or prevent symptoms of ADPKD and other diseases characterized by dysregulated mTOR activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current FDA-approved treatments (tolvaptan and lixivaptan) are used to slow cyst growth, then disease progression is reduced by approximately 30%, but severe liver injury occurs and continuous use is restricted to no more than 30 days
Solution Approach 1:
The patent uses a different molecular mechanism as an intermediary approach. Instead of targeting vasopressin receptors (which causes liver injury), the invention targets mTOR signaling pathway and metabolic abnormalities (Warburg effect) through gene therapy. This intermediary mechanism achieves disease control without the harmful liver effects of current treatments.
Solution Approach 2:
The patent changes the therapeutic parameter from pharmacological inhibition of vasopressin receptors to genetic modification of metabolic pathways. By altering the fundamental parameter of treatment modality (from drug-based to gene-based therapy), the invention avoids the liver toxicity associated with current pharmacological approaches while maintaining disease control efficacy.
2Reliability
If mTOR inhibitor drugs (sirolimus and everolimus) are used to target cyst growth, then the mechanism addresses mTOR-promoted cyst growth, but human clinical trials found no clinical benefit and even evidence of harm
Solution Approach 1:
The patent segments the complex mTOR signaling pathway into specific metabolic targets (glycolysis, oxidative phosphorylation). Instead of broad mTOR inhibition which causes harm, the invention selectively targets metabolic abnormalities (Warburg effect) through gene therapy, achieving cyst growth inhibition without the harmful side effects of non-selective mTOR inhibitors.
Solution Approach 2:
The patent replaces the mechanical/pharmacological approach of mTOR inhibition with a genetic/biological approach. By using gene therapy to restore normal metabolic function rather than pharmacologically blocking mTOR, the invention achieves the same therapeutic goal (cyst growth inhibition) without the harmful effects of current mTOR inhibitor drugs.
3Reliability
If large amounts of water are consumed to delay cyst progression, then rodent models show delayed progression, but human trials show increased urine protein loss
Solution Approach 1:
The patent introduces gene therapy as an intermediary mechanism to address cyst progression. Instead of relying on water consumption (which causes protein loss), the invention uses genetic modification to directly correct metabolic abnormalities and cyst formation mechanisms, achieving progression delay without the harmful effect of increased urine protein loss.
4Loss of time
If a single curative administration is achieved through gene therapy, then economic and care-related burdens are reduced, but the complexity of delivering therapeutic polypeptides and nucleic acids increases
Solution Approach 1:
The patent performs preliminary action by establishing permanent genetic correction through a single administration. The therapeutic polypeptides and nucleic acids are delivered once to permanently correct the underlying genetic defect, eliminating the need for repeated treatments. This preliminary genetic modification achieves long-term curative effect despite the initial complexity of the delivery system.
Data Source
AI summary
PC1-CTT polypeptides for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) are provided and can be or include PC1-CTT (SEQ ID NO:1) or a functional fragment or variant thereof. In some embodiments, the PC1-CTT polypeptide is a fusion protein or conjugate further including a functional element such as a protein transduction domain, fusogenic polypeptide, targeting signal, or expression and/or purification tag. Nucleic acids encoding the disclosed PC1-CTT polypeptides and other therapeutic proteins are also provided. In some embodiments, the nucleic acid encodes a TOP or TOP-like motif. The nucleic acids can be RNA or DNA, and can be, for example, a vector such as a plasmid or viral vector, or an mRNA. Methods of treatment are provided and typically include administering a subject in need thereof an effective amount of a disclosed polypeptide or nucleic acid.